| Safety and efficacy of insulin degludec/liraglutide (ID egLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the … HW Rodbard, BW Bode, SB Harris, L Rose, L Lehmann, H Jarlov, ... Diabetic Medicine 34 (2), 189-196, 2017 | 89 | 2017 |
| A novel nonsense mutation in PAX9 is associated with marked variability in number of missing teeth L Hansen, S Kreiborg, H Jarlov, E Niebuhr, H Eiberg European Journal of Oral Sciences 115 (4), 330-333, 2007 | 60 | 2007 |
| Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to … HW Rodbard, BW Bode, SB Harris, L Rose, L Lehmann, H Jarlov, ... Diabet Med 34 (2), 189-196, 2017 | 25 | 2017 |
| Type 2 diabetes patients reach target glycemic control faster using IDegLira than either insulin degludec or liraglutide given alone T Vilsbøll, J Vora, H Jarlov, K Kvist, L Blonde Clinical Drug Investigation 36, 293-303, 2016 | 15 | 2016 |
| IDegLira in insulin-naïve patients with type 2 diabetes (T2D) inadequately controlled on sulfonylureas (SU) alone or in combination with metformin: the DUAL IV study HW Rodbard, BW Bode, SB Harris, L Rose, L Lehmann, H Jarlov, ... Diabetes 64, A255-A256, 2015 | 15 | 2015 |
| Incidence of Gastrointestinal Side Effects Similar between IDeg-Lira and Non-GLP-1RA Comparators VR Aroda, E Jaeckel, H Jarlov, TJ Abrahamsen, T Vilsboll Diabetes 64, A257-A257, 2015 | 12 | 2015 |
| ARISE—a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 … GR Fulcher, H Jarlov, JS Piltoft, KP Singh, L Liu, M Mohamed, ... Endocrine 74, 530-537, 2021 | 6 | 2021 |
| Lower rate of hypoglycemia with IDegLira vs. insulin glargine regardless of dosing time or hypoglycemia definition in patients with type 2 diabetes P Norwood, RC Chen, E Jaeckel, I Lingvay, H Jarlov, L Lehmann, ... Diabetes 65, A105-A106, 2016 | 5 | 2016 |
| Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition … P Norwood, R Chen, E Jaeckel, I Lingvay, H Jarlov, L Lehmann, S Heller Diabetes, Obesity and Metabolism 19 (11), 1562-1569, 2017 | 4 | 2017 |
| IDegLira, a combination of insulin degludec and liraglutide, enables patients with type 2 diabetes to reach target glycaemic control faster than its individual components alone T Vilsboll, J Vora, H Jarlov, K Kvist, L Blonde Diabetologia 57, S339-S339, 2014 | 4 | 2014 |
| IDegLira in insulin-naive patients with type 2 diabetes (T2D) inade-quately controlled on sulphonylureas (SU) alone or combined with metformin: The DUAL IV Study HW Rodbard, BW Bode, S Harris, L Rose, LM Lehmann, H Jarlov, ... DIABETOLOGIA 58, S402-S402, 2015 | 2 | 2015 |
| Similar incidence of gastrointestinal side effects between IDegLira and non-glucagon-like peptide-1 receptor agonist comparators V Aroda, E Jaeckel, H Jarlov, TJ Abrahamsen, T Vilsboll Diabetologia 58, S401-S401, 2015 | 2 | 2015 |
| Insulin degludec/liraglutide (ideglira) improves patient-reported outcomes in subjects with Type 2 diabetes inadequately controlled on insulin glargine (iglar) plus metformin … A Viljoen, M Brod, FC Perez Manghi, PA Garcia-Hernandez, P Norwood, ... Diabetic Medicine 33, 65-65, 2016 | 1 | 2016 |
| Insulin degludec/liraglutide (IDegLira) improves patient-reported outcomes in subjects with type 2 diabetes uncontrolled on insulin glargine plus metformin: DUALV I Lingvay, FC Manghi, PA García-Hernández, P Norwood, H Jarlov, ... Diabetologia 58, S400-S400, 2015 | 1 | 2015 |
| Insulin degludec/liraglutide (IDegLira) improves patient-reported impacts in subjects with type 2 diabetes (T2D) inadequately controlled on insulin glargine (IG) plus metformin … M Brod, FCP Manghi, PA Garcia-Hernandez, P Norwood, H Jarlov, ... Diabetes 64, A644-A644, 2015 | 1 | 2015 |
| Correction: ARISE—a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with … GR Fulcher, H Jarlov, JS Piltoft, KP Singh, L Liu, M Mohamed, ... Endocrine, 1-1, 2022 | | 2022 |
| Exploring the mechanisms behind better PPG control with faster aspart H Jarlov International Congress of Diabetes and Metabolism 2018, 114-114, 2018 | | 2018 |
| Lower rate of hypoglycaemia with IDegLira vs insulin glargine regardless of dosing time or hypoglycaemia definition in patients with Type 2 diabetes P Norwood, R Chen, E Jaeckel, I Lingvay, H Jarlov, L Lehmann, S Heller DIABETIC MEDICINE 34, 142-143, 2017 | | 2017 |
| Des taux plus faibles d’hypoglycémies avec insuline degludec/liraglutide (IDegLira) versus insuline GlargineU100 (IGlar U100) chez les diabétiques de type 2 quels que soient l … M Marre, N Belhatem, P Norwood, R Chen, E Jaeckel, I Lingvay, H Jarlov, ... Diabetes & Metabolism 43 (2), A114, 2017 | | 2017 |
| Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition … R Chen, S Heller, E Jaeckel, H Jarlov, L Lehmann, I Lingvay, P Norwood Wiley-Blackwell Publishing Ltd, 2017 | | 2017 |
